Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics' stock has been impacted by several events over the past six months. In November 2025, topline data from the Phase 2 PIPE-307 VISTA trial for RRMS showed an acceptable safety profile but did not meet efficacy endpoints. In December 2025, the company announced the pricing of an upsized public offering expecting gross proceeds of approximately $90.0 million. In October 2025 and March 2026, the company reported its third and fourth-quarter financial results, affirming key clinical development milestones and extending its projected cash runway. In March 2026, patient dosing was initiated in the PROPEL-IPF Phase 2 trial. Also in March 2026, the company reported an inducement grant of a non-qualified stock option to a new non-executive employee. The stock price increased by 57.35% between March 24, 2025, and March 20, 2026.

As a clinical-stage biopharmaceutical company without commercially available products, Contineum Therapeutics does not have demand seasonality in the traditional sense. The company's focus is on research and development, with future commercialization dependent on successful clinical trials and regulatory approvals.

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for neuroscience, inflammation, and immunology indications. The company's pipeline includes PIPE-791, a LPA1R inhibitor in development for IPF, PrMS, and chronic pain, with patient dosing initiated in a Phase 2 trial for IPF and topline data from a Phase 1b trial in chronic pain expected in Q2 2026. PIPE-307, a M1R inhibitor, is in development for depression and RRMS, with Johnson & Johnson initiating a Phase 2 trial in December 2024.

Contineum Therapeutics is headquartered in San Diego, California, and its primary operations are based in the U.S. Clinical trials, such as the PROPEL-IPF trial, may have a global reach.

Contineum Therapeutics maintains a "Moderate Buy" consensus rating from analysts, with a positive outlook from the financial community. The initiation of the Phase 2 PROPEL-IPF trial contributes positively to its scientific reputation. However, the Phase 2 PIPE-307 VISTA trial not meeting its efficacy endpoints could be a point of concern. The company's ability to secure funding and maintain a projected cash runway into mid-2029 demonstrates financial stability.

Contineum Therapeutics, Inc. has a significant number of institutional owners and shareholders, including Suvretta Capital Management, Janus Henderson Group Plc, RA Capital Management, L.p., Johnson & Johnson Innovation - JJDC, Inc., Franklin Resources Inc, Balyasny Asset Management Llc, Perceptive Advisors Llc, Baker Bros. Advisors Lp, Vanguard Group Inc, and Millennium Management Llc.